Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121190 | 0.83 | ADRB2 (0.40) | PIK3CGCCR5ADRB2ADRB1DRD2 | |
| SCHEMBL5119595 | 0.82 | ADRB2 (0.40) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL776314 | 0.78 | ADRB2 (0.39) | PIK3CGADRB2ADRB1ADORA3DRD2 | |
| SCHEMBL384325 | 0.78 | ADRB2 (0.39) | PIK3CGADRB2ADRB1ADORA3DRD2 | |
| SCHEMBL16999077 | 0.77 | ADORA3 (0.38) | PIK3CGADRB2ADRB1ADORA3DRD2 | |
| SCHEMBL27415356 | 0.77 | ADORA3 (0.37) | PIK3CGADRB2ADRB1ADORA3DRD2 | |
| SCHEMBL99134 | 0.75 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL14681026 | 0.75 | ADORA3 (0.40) | PIK3CGADRB2ADRB1ADORA3DRD2 | |
| SCHEMBL2568651 | 0.75 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL30490482 | 0.75 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138837-B1 | INDACATEROL FREE BASE IN SOLID FORM | CRYSTAL PHARMA SAU (ES) | 2021-11-24 | — | — | EP | disclosed |
| EP-3848354-A1 | PROCESS FOR THE PREPARATION OF INDACATEROL AND INTERMEDIATES THEREOF | Crystal Pharma, S.A.U. (ES) | 2021-07-14 | — | — | EP | disclosed |
| EP-2897937-B1 | PROCESS FOR THE PREPARATION OF INDACATEROL AND INTERMEDIATES THEREOF | CRYSTAL PHARMA SAU (ES) | 2017-12-06 | — | — | EP | disclosed |
| EP-3138837-A1 | INDACATEROL FREE BASE IN SOLID FORM | Crystal Pharma, S.A.U. (ES) | 2017-03-08 | — | — | EP | disclosed |
| US-9475772-B2 | Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof | CRYSTAL PHARMA S.A.U. (ES) | 2016-10-25 | — | — | US | disclosed |
| US-20150225346-A1 | METHODS FOR THE PREPARATION OF INDACATEROL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | CRYSTAL PHARMA S.A.U. (ES) | 2015-08-13 | — | — | US | disclosed |
| US-7402598-B2 | Arylethanolamine β2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
| EP-1525180-A2 | ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004016578-A2 | ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | ADRB2, ADRB1, ADRA2A | PIK3CG 2595/4885MCHR1 258/4885CCR5 1604/4885 |
| US-20150225346-A1 | METHODS FOR THE PREPARATION OF INDACATEROL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SQLE, HSD11B1, CYP51A1 | PIK3CG 1594/4885MCHR1 2305/4885CCR5 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.